Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in South Korea / NCT07754175
Recruiting Observational

A Multicenter, Open-Label, Single-Arm Extension Study to Evaluate the Safety and Efficacy of FURESTEM-OA-Kit Inj. in Knee Osteoarthritis Patients Who Received Placebo in the K0701 Phase 2a Trial

NCT07754175 · tracked via the Priya Life Science South Korea tracker
Sponsor
Kang Stem Biotech Co., Ltd
Phase
Observational
Started
2026-07-20
Last updated
2026-08-10

Condition(s) studied

Knee Osteoarthritis

Study summary

A Multicenter, Open-Label, Single-Arm Extension Study to Evaluate the Safety and Efficacy of FURESTEM-OA-Kit Inj. in Knee Osteoarthritis Patients Who Received Placebo in the K0701 Phase 2a Trial

Eligibility

Sex
ALL
Min age
19 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Participants who received placebo in the K0701 clinical trial and completed the Long-term follow-up study * Participants who voluntarily provide written informed consent to participate in this extension study Exclusion Criteria: Participants meeting any of the following criteria: * Participants whom the investigator considers unsuitable for participation in this extension study. * Pregnant or breastfeeding women, and women of childbearing potential or men who do not agree to use an appropriate method of contraception during the study

Primary outcome measure(s)

  • Incidence of Adverse Event, AESI(Adverse Event of Special Interest) — 5 years follow-up after treatment

Trial sites (2)

FacilityCityRegionStatus
CHA University Bundang Medical Center Seoul South Korea Recruiting
Kyung Hee University Hospital Seoul South Korea Not Yet Recruiting

More Kang Stem Biotech Co., Ltd. trials in South Korea

Long-term Follow-up Study to Evaluate the Safety and Explore the Efficacy of Multiple Doses of FURESTEM-AD Inj Starting soon
Long-Term Follow-up Study of FURESTEM-AD in Patients With Atopic Dermatitis(K0106) Active, not recruiting

Other trials for the same condition

Follow-up Study for Participants of Jointstem Phase 3 Clinical Trial Active, not recruiting
Long-Term Study of CartiPRO for Knee Pain Due to Osteoarthritis or Cartilage Damage Active, not recruiting
Pivotal Clinical Trial to Evaluate the Efficacy and Safety After NPNP-001 Application in Patients with Knee Osteoarthritis. Enrolling by invitation
MORA Cure for Knee Osteoarthritis With Anterior Knee Pain Active, not recruiting
Evaluation Safety and Explore Efficacy Long-term Follow-up Study on Subjects Receiving SMUP-IA-01 or Active Control Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07754175 on ClinicalTrials.gov ↗ ← All trials in South Korea